Regulatory and Safety: Obesity Drugs
Diabetes & Obesity Series
Safety and Regulatory Aspects of Obesity Drugs
Subscribe to RSS feed of this series
Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace
Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025